Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises People Ventures in conjunction with an investment in Leia Health
Mandate

Vinge advises People Ventures in conjunction with an investment in Leia Health

December 21, 2022 Life Sciences & Health

Vinge has advised the Danish VC fund People Ventures in conjunction with its investment in Leia Health, which has developed an app designed to map physical and mental health for postpartum women.

Leia Health has added MSEK 14 in its latest investment round and, in addition to People Ventures, Norrsken and Unconventional Ventures are the main investors.

Vinge’s team primarily consisted of  Johan Winnerblad, Eléonore Friberg, Jonna Skog, Ebba Nyberg and Karolina Fuhrman.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025